跳转至内容
Merck
CN
  • Implications of premature ovarian failure on bone turnover markers and bone mineral density.

Implications of premature ovarian failure on bone turnover markers and bone mineral density.

Clinical and experimental obstetrics & gynecology (2014-05-02)
N Kurtoglu-Aksoy, S E Akhan, E Bastu, F Gungor-Ugurlucan, A Telci, A C Iyibozkurt, S Topuz
摘要

Premature ovarian failure (POF) is the cessation of ovarian function before the age of 40. The loss of ovarian function, whether premature or not, has an overwhelming impact on female skeletal health, leading to an increased risk of developing osteoporosis because of the lengthened time of exposure to reduced estrogen. The objective of this study was to compare the implications of premature ovarian failure on bone turnover markers and bone mineral density in patients under the age of 40. Sixty-one patients with a diagnosis of POF were selected for this prospective study. Patients were divided into two groups according to age, patients < 30 years old (n = 30), and patients > or = 30 years old (n = 31). Between the two age sub-groups (< 30 and > or = 30 years old), there was a significant difference in menopause rating scale (MRS), lumbar spine t-score, N-telopeptides crosslinks (NTx), and serum bone specific alkaline phosphatase (bALP) between the two age groups (10.93 +/- 7.79 vs 17.38 +/- 8.62; -1.84 +/- 1.47 vs -1.06 +/- 0.93; 58.80 +/- 21.32 vs 41.1 +/- 11.37; 48.99 +/- 42.16 vs 23.76 +/- 10.08, respectively). It is apparent that bone mineral density (BMD) is commonly less in women with POF than normal healthy women. Therefore, measurement of BMD is warranted. At this time, it is not clear how often the tests should be carried out to evaluate BMD. Further prospective studies are required to establish guidelines. However, it seems reasonable to monitor women with POF yearly for the presence of any endocrine dysfunction and to assess BMD at periodic intervals.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
碱性磷酸酶 来源于牛肠粘膜, buffered aqueous solution, ≥2,000 DEA units/mg protein
Sigma-Aldrich
碱性磷酸酶 来源于牛肠粘膜, lyophilized powder, ≥10 DEA units/mg solid
Sigma-Aldrich
碱性磷酸酶 来源于牛肠粘膜, BioUltra, ≥5,700 DEA units/mg protein
Sigma-Aldrich
碱性磷酸酶 来源于牛肠粘膜, ≥2,000 DEA units/mg protein
Sigma-Aldrich
碱性磷酸酶 来源于大肠杆菌, lyophilized powder, 30-60 units/mg protein (in glycine buffer)
Sigma-Aldrich
碱性磷酸酶 来源于牛肠粘膜, ≥5,500 DEA units/mg protein
Sigma-Aldrich
碱性磷酸酶 来源于大肠杆菌, buffered aqueous glycerol solution, 20-50 units/mg protein (in glycine buffer)
Sigma-Aldrich
碱性磷酸酶 来源于牛肠粘膜, buffered aqueous glycerol solution, ≥4,000 DEA units/mg protein
Sigma-Aldrich
碱性磷酸酶 来源于大肠杆菌, ammonium sulfate suspension, 30-90 units/mg protein (modified Warburg-Christian, in glycine buffer)
Sigma-Aldrich
碱性磷酸酶 来源于猪肾脏, lyophilized powder, ≥100 DEA units/mg protein
Sigma-Aldrich
磷酸酶(碱性) 来源于小牛肠粘膜, suitable for enzyme immunoassay, solution (clear, colorless), ~2500 U/mg protein (~10 mg/ml)
Sigma-Aldrich
磷酸酶,碱性虾, ≥900 DEA units/mL, buffered aqueous glycerol solution, recombinant, expressed in proprietary host
Sigma-Aldrich
磷酸酶(碱性) 牛, recombinant, expressed in Pichia pastoris, ≥4000 units/mg protein